The Latest Cardiac and Vascular News
WINNIPEG, Dec. 17, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the Shortened AGGRASTAT® (tirofiban hydrochloride) injection versus Integrilin® (eptifibatide) in Percutaneous Coronary Intervention (SAVI-PCI) Clinical Trial. SAVI-PCI was a randomized, multicenter, open-label study enrolling 535 patients at 13 sites […]
NANJING, China, Dec. 16, 2019 /PRNewswire/ — TransThera Biosciences Co. Ltd, a clinical-stage biotechnology company based in Nanjing, China, announced today that the U.S. Food and Drug Administration (FDA) has granted the company’s Investigational New Drug (IND) application for TT-00920, a novel small molecule inhibitor of Phosphodiesterase 9 (PDE 9) for the treatment of chronic heart failure. […]
VANCOUVER, Dec. 17, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the […]
NEW YORK, Dec. 17, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that its Phase 3 trial of Revascor for advanced chronic heart failure has surpassed the number of primary endpoint events required for trial completion. This cardiovascular outcomes trial has now initiated final study visits […]
Novoheart engineered the world’s first “human heart-in-a-jar” as part of its proprietary MyHeart™ platform Novoheart receives exclusive license from Harvard University to integrate pioneering bioreactor technology that accommodates model ventricles and optional valves into the “human heart-in-a-jar” model The resultant next-generation model will have unparalleled biofidelity as well as enhanced […]
Rouen, France, December 16, 2019 – Robocath, a company that designs, develops and commercializes cardiovascular robotic systems for the treatment of vascular diseases, today announces it has successfully completed six robotic coronary angioplasties with R-One™, a first for the continent of Africa. These Percutaneous Coronary Interventions (PCI) were performed by Dr Faizel […]
BOSTON–(BUSINESS WIRE)–A pivotal, multi-center clinical trial to explore a promising new therapy to reduce heart failure rates by changing the way heart attack patients are treated is now underway. The first patient has enrolled in the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial. The first enrollment took […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) announces initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial (RCT), which will explore whether unloading the heart’s left ventricle for 30 minutes with an Impella heart pump prior to opening blocked arteries will reduce infarct size after a heart attack and lead to […]
Personalized Volume Management System : 2nd generation automated fluid management technology MILFORD, Mass., Dec. 13, 2019 /PRNewswire/ — Reprieve Cardiovascular®, a pioneering medical device company focused on improving outcomes for patients suffering from acute decompensated heart failure (ADHF), today announced the results of the first-in-human clinical trial with the company’s second generation device, […]
WINNIPEG, Dec. 12, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH), (OTC: MCUJF), a cardiovascular pharmaceutical company, is pleased to announce the completion of the FABOLUS-FASTER Phase 4 trial, a randomized, open-label, multi-center trial assessing different regimens of intravenous platelet inhibitors, notably tirofiban (an IV GP IIb/IIIa inhibitor) and cangrelor (an […]
